Skip to content
approvedHormone Regulation

Gonadorelin

Also known as: GnRH, Gonadotropin-Releasing Hormone, LHRH, Factrel, Lutrelef

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), a decapeptide produced by the hypothalamus that controls the entire reproductive hormonal axis. FDA-approved as Factrel for diagnostic evaluation of pituitary gonadotroph function, it stimulates the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. It is also used off-label in pulsatile delivery for hypothalamic amenorrhea and male hypogonadism, and has gained attention in hormone optimization clinics as an alternative to hCG for maintaining testicular function during testosterone replacement therapy.

3 cited references·5 researched benefits

Quick Answer

Gonadorelin is the synthetic form of natural gonadotropin-releasing hormone (GnRH), a decapeptide that stimulates LH and FSH release from the pituitary gland. FDA-approved for diagnostic testing of pituitary function, it is also used off-label via pulsatile delivery to treat hypothalamic amenorrhea and to preserve testicular function during testosterone therapy. Its ultra-short half-life of 2-4 minutes mimics natural pulsatile secretion.

Key Facts

Mechanism
Gonadorelin binds to GnRH receptors (GnRHR) on gonadotroph cells in the anterior pituitary gland. When delivered in a pulsatile fashion mimicking natural hypothalamic secretion (approximately every 60-120 minutes), it stimulates synthesis and release of both LH and FSH, which in turn drive gonadal steroidogenesis and gametogenesis. Continuous (non-pulsatile) administration paradoxically downregulates GnRH receptors and suppresses gonadotropin release — the principle exploited by GnRH agonist drugs like leuprolide. The native peptide is rapidly cleaved by endopeptidases in the hypothalamic-hypophyseal portal circulation, giving it a very short half-life.
Research Status
approved
Half-Life
~2-4 minutes
Molecular Formula
C₅₅H₇₅N₁₇O₁₃
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • Diagnostic evaluation of pituitary gonadotroph function — FDA-approved test to distinguish pituitary from hypothalamic causes of hypogonadismstrong
  • Restores fertility in hypothalamic amenorrhea when delivered via pulsatile pump, with ovulation rates exceeding 90% in clinical studiesstrong
  • Maintains testicular function and spermatogenesis during testosterone replacement therapy by preserving endogenous LH/FSH stimulationmoderate
  • Preserves endogenous testosterone production — used in hormone optimization protocols as an alternative to hCG for HPT axis supportmoderate
  • Pulsatile delivery achieves more physiologic gonadotropin patterns compared to exogenous hCG, potentially reducing estrogen spikespreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous or subcutaneous (diagnostic)100 mcgSingle doseFDA-approved diagnostic dose. Blood drawn at baseline and 15, 30, 45, 60, and 120 minutes post-injection to measure LH and FSH response.
Subcutaneous pulsatile pump (fertility)5-20 mcg per pulseEvery 60-120 minutes via portable pumpMimics physiologic GnRH pulsatility. Typical protocols use 5 mcg pulses every 90 minutes. Requires specialized portable infusion pump.
Subcutaneous injection (TRT adjunct, off-label)100-200 mcg2-3 times per weekUsed in hormone optimization clinics to maintain testicular function during testosterone therapy. Not FDA-approved for this indication.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Headache — reported in approximately 5-10% of patients receiving diagnostic dosescommon
  • Nausea and abdominal discomfort — mild gastrointestinal effects that typically resolve quicklycommon
  • Flushing and lightheadedness — transient vasomotor symptoms following injectioncommon
  • Injection site reactions — pain, swelling, or redness at the subcutaneous or intravenous injection sitecommon
  • Ovarian hyperstimulation syndrome (OHSS) — rare but serious risk when used for fertility induction; requires monitoring with ultrasoundserious
  • Anaphylaxis — extremely rare allergic reactions have been reported with repeated diagnostic useserious

Frequently Asked Questions

What is gonadorelin used for in TRT clinics?
Gonadorelin is increasingly prescribed by hormone optimization clinics as an adjunct to testosterone replacement therapy (TRT). When men take exogenous testosterone, the hypothalamic-pituitary-gonadal axis shuts down, causing testicular atrophy and infertility. Gonadorelin injections 2-3 times per week stimulate LH and FSH release, helping maintain testicular size, spermatogenesis, and some endogenous testosterone production. It has become more popular since the FDA restricted compounding of hCG in some contexts.
How is gonadorelin different from GnRH agonists like leuprolide?
Gonadorelin is identical to natural GnRH and has a half-life of only 2-4 minutes, so it stimulates a brief pulse of LH/FSH when injected. GnRH agonists like leuprolide are modified analogs with much longer half-lives (hours) and greater receptor affinity. While a single leuprolide dose initially stimulates gonadotropins (the "flare" effect), continuous exposure causes receptor downregulation and ultimately suppresses LH, FSH, and sex steroids — the opposite of gonadorelin's intended effect.
Can gonadorelin replace hCG for maintaining fertility on TRT?
Gonadorelin is used as an alternative to hCG for this purpose, though the evidence is less robust. hCG directly mimics LH at the testicular level and has decades of fertility data. Gonadorelin works upstream by stimulating pituitary LH release, but its very short half-life means intermittent subcutaneous injections may not provide sustained gonadotropin stimulation. Some clinicians find it less effective than hCG, while others report adequate testicular maintenance. Head-to-head clinical trials are lacking.
What does the gonadorelin stimulation test show?
The GnRH stimulation test (using 100 mcg IV gonadorelin) differentiates hypothalamic from pituitary causes of hypogonadism. In a normal response, LH rises 3-6 fold within 15-45 minutes. An absent or blunted response suggests pituitary failure (hypopituitarism), while an exaggerated response may indicate primary gonadal failure. A delayed but present response suggests hypothalamic dysfunction with intact pituitary function. The test is essential in the workup of delayed puberty, amenorrhea, and infertility.
Is gonadorelin the same as Lupron (leuprolide)?
No, they are very different despite both acting on the GnRH receptor. Gonadorelin is the natural GnRH peptide with a 2-4 minute half-life that transiently stimulates gonadotropin release. Leuprolide (Lupron) is a synthetic GnRH analog with modifications that make it resistant to enzymatic degradation, giving it a half-life of hours. Chronic leuprolide suppresses sex hormones (used for prostate cancer, endometriosis), while gonadorelin is used to stimulate the reproductive axis.

References

  1. 1
    Synthetic luteinizing hormone-releasing factor: a potent stimulator of gonadotropin release in man(1983)PubMed ↗
  2. 2
    Pulsatile GnRH therapy for induction of ovulation in hypothalamic amenorrhea(1987)PubMed ↗
  3. 3
    GnRH agonists and antagonists in reproductive medicine: a review(2004)PubMed ↗

Latest Research

Last updated: 2026-02-19